A multicenter Phase II study of Epirubicin (E) with low-dose Herceptin (LD-H) as a first line treatment in HER-2 overexpressing metastatic breast cancer (MBC): Preliminary results

被引：0
|
作者：
De Tursi, M.
Carella, C.
Ricevuto, E.
Marchetti, P.
Gennari, A.
Orlandini, C.
Frassoldati, A.
Conte, P.
Iacobelli, S.
机构：
[1] Univ G dAnnunzio, Dept Oncol & Neurosci, Chieti, Italy
[2] Univ Aquila, Dept Oncol, I-67100 Laquila, Italy
[3] Univ Pisa, Dept Oncol, I-56100 Pisa, Italy
[4] Univ Modena, Dept Oncol, I-41100 Modena, Italy
来源：
EJC SUPPLEMENTS | 2005年 / 3卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：116 / 116
页数：1
相关论文
共 50 条
  • [21] Weekly docetaxel and gemcitabine following docetaxel plus epirubicin or vinorelbine as first line treatment of metastatic breast cancer: Results of a multicenter phase II study
    Riccardi, A
    Brugnatelli, S
    Danova, M
    Giordano, M
    Pugliese, P
    Luchena, G
    Grasso, D
    Trotti, G
    Berte, R
    Pansini, G
    Tinelli, C
    TUMORI, 2006, 92 (01) : 6 - 12
  • [22] Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II and pharmacokinetic study in Japan
    Tokudome, Nahomi
    Ito, Yoshinori
    Hatake, Kiyohiko
    Toi, Masakazu
    Sano, Muneaki
    Iwata, Hiroji
    Sato, Yasuyuki
    Saeki, Toshiaki
    Aogi, Kenjiro
    Takashima, Shigemitsu
    ANTI-CANCER DRUGS, 2008, 19 (07) : 753 - 759
  • [23] Low-dose capecitabine plus docetaxel as first-line therapy for metastatic breast cancer: phase II results
    Michalaki, Vasiliki
    Gennatas, Spyridon
    Gennatas, Konstantine
    ANTI-CANCER DRUGS, 2009, 20 (03) : 204 - 207
  • [24] Randomized phase II study of docetaxel vs. epirubicin/cyclophosphamide to optimize first-line therapy of metastatic breast cancer (MBC): preliminary results of the TIPP study.
    Wasemann, C
    Di Liberto, A
    Ertan, K
    Schmidt, W
    Friedrich, M
    BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 : S89 - S89
  • [25] Low-dose capecitabine monotherapy in HER-2 negative metastatic breast cancer: a retrospective study.
    Ambros, T.
    Zeichner, S. B.
    Zaravinos, J.
    Montero, A. J.
    Ahn, E.
    Mani, A.
    Kronish, L.
    Mahtani, R. L.
    Vogel, C. L.
    CANCER RESEARCH, 2012, 72
  • [26] Phase II study of single agent oral vinorelbine as first-line treatment in patients with HER-2 negative metastatic breast cancer
    Mansour, Maged
    Mourad, Cynthia
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 72 (02) : 429 - 435
  • [27] Gemzar®(Ci) and epirubicin (E) in patients (pts) with metastatic breast cancer(MBC):: Final results of a phase I dose finding study
    Fumoleau, P
    Viens, P
    Dieras, V
    Pujade-Lauraine, E
    Espie, M
    Kayitalire, L
    Rongier, AM
    Pouillart, P
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S292 - S292
  • [28] Phase II study of single agent oral vinorelbine as first-line treatment in patients with HER-2 negative metastatic breast cancer
    Maged Mansour
    Cynthia Mourad
    Cancer Chemotherapy and Pharmacology, 2013, 72 : 429 - 435
  • [29] First line treatment with weekly docetaxel, vinorelbine, and trastuzumab in HER2 overexpressing metastatic breast cancer (HER2+MBC): A Minnie Pearl Cancer Research Network phase II trial.
    Yardley, DA
    Greco, FA
    Porter, LL
    Burris, HA
    Phelps, C
    Webb, C
    Schlabach, L
    Fichtel, LM
    Hainsworth, JD
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 37S - 37S
  • [30] A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer
    Rugo, Hope S.
    Chien, A. Jo
    Franco, Sandra X.
    Stopeck, Alison T.
    Glencer, Alexa
    Lahiri, Soumi
    Arbushites, Michael C.
    Scott, Janet
    Park, John W.
    Hudis, Clifford
    Nulsen, Ben
    Dickler, Maura N.
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 134 (01) : 13 - 20
12345